Aarti Surfactants Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 29, 2025, 7:28 pm

Quick Insight

Aarti Surfactants Ltd, with a current share price of 471 and a market cap of 398 Cr., displays a P/E ratio of 31.6, indicating a relatively high valuation compared to its earnings. The company's ROE stands at 5.14%, while ROCE is at 8.50%, suggesting room for improvement in capital efficiency. With an OPM of 5.39%, profitability margins may be a concern. The firm's net profit of 15 Cr. highlights modest earnings. Notably, Aarti Surfactants Ltd holds reserves of 224 Cr. and carries borrowings of ₹110 Cr., resulting in a comfortable ICR of 3.93x. Overall, investors should carefully evaluate the company's growth prospects and operational efficiency before making investment decisions.

Competitors of Aarti Surfactants Ltd

All Competitor Stocks of Aarti Surfactants Ltd

Quarterly Result

Last Updated: August 20, 2025, 12:50 am

Below is a detailed analysis of the quarterly data for Aarti Surfactants Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 215.90 Cr.. The value appears strong and on an upward trend. It has increased from 202.05 Cr. (Mar 2025) to 215.90 Cr., marking an increase of 13.85 Cr..
• For Expenses, as of Jun 2025, the value is 204.27 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 182.36 Cr. (Mar 2025) to 204.27 Cr., marking an increase of 21.91 Cr..
• For Operating Profit, as of Jun 2025, the value is 11.63 Cr.. The value appears to be declining and may need further review. It has decreased from 19.69 Cr. (Mar 2025) to 11.63 Cr., marking a decrease of 8.06 Cr..
• For OPM %, as of Jun 2025, the value is 5.39%. The value appears to be declining and may need further review. It has decreased from 9.75% (Mar 2025) to 5.39%, marking a decrease of 4.36%.
• For Other Income, as of Jun 2025, the value is 0.04 Cr.. The value appears to be declining and may need further review. It has decreased from 1.14 Cr. (Mar 2025) to 0.04 Cr., marking a decrease of 1.10 Cr..
• For Interest, as of Jun 2025, the value is 3.28 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.26 Cr. (Mar 2025) to 3.28 Cr., marking an increase of 0.02 Cr..
• For Depreciation, as of Jun 2025, the value is 4.35 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4.41 Cr. (Mar 2025) to 4.35 Cr., marking a decrease of 0.06 Cr..
• For Profit before tax, as of Jun 2025, the value is 4.04 Cr.. The value appears to be declining and may need further review. It has decreased from 13.16 Cr. (Mar 2025) to 4.04 Cr., marking a decrease of 9.12 Cr..
• For Tax %, as of Jun 2025, the value is 27.23%. The value appears to be increasing, which may not be favorable. It has increased from 26.22% (Mar 2025) to 27.23%, marking an increase of 1.01%.
• For Net Profit, as of Jun 2025, the value is 2.94 Cr.. The value appears to be declining and may need further review. It has decreased from 9.72 Cr. (Mar 2025) to 2.94 Cr., marking a decrease of 6.78 Cr..
• For EPS in Rs, as of Jun 2025, the value is 3.48. The value appears to be declining and may need further review. It has decreased from 11.49 (Mar 2025) to 3.48, marking a decrease of 8.01.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 3:20 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: August 11, 2025, 3:10 pm

Below is a detailed analysis of the balance sheet data for Aarti Surfactants Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 8.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 8.00 Cr..
• For Reserves, as of Mar 2025, the value is 224.00 Cr.. The value appears strong and on an upward trend. It has increased from 210.00 Cr. (Mar 2024) to 224.00 Cr., marking an increase of 14.00 Cr..
• For Borrowings, as of Mar 2025, the value is 110.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 99.00 Cr. (Mar 2024) to 110.00 Cr., marking an increase of 11.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 134.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 105.00 Cr. (Mar 2024) to 134.00 Cr., marking an increase of 29.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 477.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 422.00 Cr. (Mar 2024) to 477.00 Cr., marking an increase of 55.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 206.00 Cr.. The value appears to be declining and may need further review. It has decreased from 208.00 Cr. (Mar 2024) to 206.00 Cr., marking a decrease of 2.00 Cr..
• For CWIP, as of Mar 2025, the value is 13.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.00 Cr. (Mar 2024) to 13.00 Cr., marking an increase of 5.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 259.00 Cr.. The value appears strong and on an upward trend. It has increased from 206.00 Cr. (Mar 2024) to 259.00 Cr., marking an increase of 53.00 Cr..
• For Total Assets, as of Mar 2025, the value is 477.00 Cr.. The value appears strong and on an upward trend. It has increased from 422.00 Cr. (Mar 2024) to 477.00 Cr., marking an increase of 55.00 Cr..

Notably, the Reserves (224.00 Cr.) exceed the Borrowings (110.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Key Financial Ratios

After reviewing the key financial ratios for Aarti Surfactants Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 17.20. This value is within the healthy range. It has decreased from 26.63 (Mar 24) to 17.20, marking a decrease of 9.43.
• For Diluted EPS (Rs.), as of Mar 25, the value is 17.19. This value is within the healthy range. It has decreased from 25.16 (Mar 24) to 17.19, marking a decrease of 7.97.
• For Cash EPS (Rs.), as of Mar 25, the value is 37.67. This value is within the healthy range. It has decreased from 44.13 (Mar 24) to 37.67, marking a decrease of 6.46.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 274.78. It has increased from 257.64 (Mar 24) to 274.78, marking an increase of 17.14.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 274.78. It has increased from 257.64 (Mar 24) to 274.78, marking an increase of 17.14.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 778.53. It has increased from 696.75 (Mar 24) to 778.53, marking an increase of 81.78.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 53.62. This value is within the healthy range. It has decreased from 73.54 (Mar 24) to 53.62, marking a decrease of 19.92.
• For PBIT / Share (Rs.), as of Mar 25, the value is 33.13. This value is within the healthy range. It has decreased from 54.60 (Mar 24) to 33.13, marking a decrease of 21.47.
• For PBT / Share (Rs.), as of Mar 25, the value is 24.45. This value is within the healthy range. It has decreased from 38.02 (Mar 24) to 24.45, marking a decrease of 13.57.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 17.18. This value is within the healthy range. It has decreased from 25.19 (Mar 24) to 17.18, marking a decrease of 8.01.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 17.18. This value is within the healthy range. It has decreased from 25.19 (Mar 24) to 17.18, marking a decrease of 8.01.
• For PBDIT Margin (%), as of Mar 25, the value is 6.88. This value is below the healthy minimum of 10. It has decreased from 10.55 (Mar 24) to 6.88, marking a decrease of 3.67.
• For PBIT Margin (%), as of Mar 25, the value is 4.25. This value is below the healthy minimum of 10. It has decreased from 7.83 (Mar 24) to 4.25, marking a decrease of 3.58.
• For PBT Margin (%), as of Mar 25, the value is 3.14. This value is below the healthy minimum of 10. It has decreased from 5.45 (Mar 24) to 3.14, marking a decrease of 2.31.
• For Net Profit Margin (%), as of Mar 25, the value is 2.20. This value is below the healthy minimum of 5. It has decreased from 3.61 (Mar 24) to 2.20, marking a decrease of 1.41.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 2.20. This value is below the healthy minimum of 8. It has decreased from 3.61 (Mar 24) to 2.20, marking a decrease of 1.41.
• For Return on Networth / Equity (%), as of Mar 25, the value is 6.25. This value is below the healthy minimum of 15. It has decreased from 9.77 (Mar 24) to 6.25, marking a decrease of 3.52.
• For Return on Capital Employeed (%), as of Mar 25, the value is 9.64. This value is below the healthy minimum of 10. It has decreased from 15.77 (Mar 24) to 9.64, marking a decrease of 6.13.
• For Return On Assets (%), as of Mar 25, the value is 3.04. This value is below the healthy minimum of 5. It has decreased from 5.05 (Mar 24) to 3.04, marking a decrease of 2.01.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.11. This value is below the healthy minimum of 0.2. It has decreased from 0.12 (Mar 24) to 0.11, marking a decrease of 0.01.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.46. This value is within the healthy range. It has increased from 0.34 (Mar 24) to 0.46, marking an increase of 0.12.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.47. It has increased from 1.43 (Mar 24) to 1.47, marking an increase of 0.04.
• For Current Ratio (X), as of Mar 25, the value is 1.35. This value is below the healthy minimum of 1.5. It has decreased from 1.54 (Mar 24) to 1.35, marking a decrease of 0.19.
• For Quick Ratio (X), as of Mar 25, the value is 0.63. This value is below the healthy minimum of 1. It has decreased from 0.77 (Mar 24) to 0.63, marking a decrease of 0.14.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.64. This value is within the healthy range. It has decreased from 5.05 (Mar 24) to 4.64, marking a decrease of 0.41.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 3.93. This value is within the healthy range. It has decreased from 4.44 (Mar 24) to 3.93, marking a decrease of 0.51.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.90. This value is below the healthy minimum of 3. It has decreased from 2.52 (Mar 24) to 1.90, marking a decrease of 0.62.
• For Enterprise Value (Cr.), as of Mar 25, the value is 446.96. It has decreased from 559.15 (Mar 24) to 446.96, marking a decrease of 112.19.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.67. This value is below the healthy minimum of 1. It has decreased from 0.94 (Mar 24) to 0.67, marking a decrease of 0.27.
• For EV / EBITDA (X), as of Mar 25, the value is 9.85. This value is within the healthy range. It has increased from 8.98 (Mar 24) to 9.85, marking an increase of 0.87.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.51. This value is below the healthy minimum of 1. It has decreased from 0.79 (Mar 24) to 0.51, marking a decrease of 0.28.
• For Price / BV (X), as of Mar 25, the value is 1.46. This value is within the healthy range. It has decreased from 2.15 (Mar 24) to 1.46, marking a decrease of 0.69.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.51. This value is below the healthy minimum of 1. It has decreased from 0.79 (Mar 24) to 0.51, marking a decrease of 0.28.
• For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.04.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness